Chinese Language Podcast: ESMO China Data, Annual CDE Report, Shanghai Biopharma Week
Regulatory Trends, Latest Data Readouts And More
Topics in this latest Chinese-language podcast include the China Center for Drug Evaluation's annual IND and NDA report, highlights of Chinese companies' data readouts at ESMO, and policy signals from the International Biopharma Industry Week Shanghai.
Chinese oncology developers including BeiGene, Ltd., Jiangsu Hengrui Medicine Co., Ltd. and Shanghai Junshi Biosciences Co., Ltd. all released new clinical data during the recent European Society for Medical Oncology (ESMO) meeting.
What were some of the highlights and notable results, in particular against emerging targets such as KRAS G12D? (Also see "ESMO 23: Kelun/Merck, Hansoh ADCs Impress With Early Data In Breast Cancer" - Scrip, 20 Oct, 2023.)
In other recent hot China biopharma topics covered in this Chinese-language podcast, China's Center for Drug Evaluation released its annual report for 2022, which highlighted several key trends in clinical trial and new drug approval activity in the country. (Also see "China New Drug Trials Momentum Tapering, Regulatory Changes Looming" - Pink Sheet, 16 Oct, 2023.)
Meanwhile, the Shanghai municipal government organized its major international biopharma week for the third year in a row from 16-20 October. Shanghai-based Scrip senior editor Dexter Yan makes some observations on his in-person attendance at the event.
If you have any suggestions, comments or ideas, please contact the authors at the email addresses above.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.